Search details
1.
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Blood
; 142(14): 1208-1218, 2023 10 05.
Article
in English
| MEDLINE | ID: mdl-37366170
2.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Article
in English
| MEDLINE | ID: mdl-34192431
3.
bDMARD can prevent the progression of AA amyloidosis to end-stage renal disease.
Ann Rheum Dis
; 2024 Apr 23.
Article
in English
| MEDLINE | ID: mdl-38653531
4.
Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
Haematologica
; 109(1): 220-230, 2024 Jan 01.
Article
in English
| MEDLINE | ID: mdl-37439344
5.
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Haematologica
; 2024 Mar 28.
Article
in English
| MEDLINE | ID: mdl-38546696
6.
Statin-based endothelial prophylaxis and outcome after allogeneic stem cell transplantation.
Eur J Clin Invest
; 53(2): e13883, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-36199203
7.
Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling.
Haematologica
; 108(4): 1105-1114, 2023 04 01.
Article
in English
| MEDLINE | ID: mdl-35770529
8.
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients less than 60 years of age: a prospective phase II study
Haematologica
; 2023 11 09.
Article
in English
| MEDLINE | ID: mdl-37941409
9.
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.
Eur J Haematol
; 111(2): 181-190, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37082839
10.
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice.
Am J Hematol
; 98(5): 720-729, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36708469
11.
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019.
Br J Haematol
; 197(1): 82-96, 2022 04.
Article
in English
| MEDLINE | ID: mdl-35166376
12.
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Blood
; 135(18): 1517-1530, 2020 04 30.
Article
in English
| MEDLINE | ID: mdl-32107537
13.
Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study.
Haematologica
; 107(5): 1054-1063, 2022 05 01.
Article
in English
| MEDLINE | ID: mdl-34162176
14.
Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells.
Cytotherapy
; 24(3): 311-319, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34711501
15.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Am J Hematol
; 97(6): 719-730, 2022 06 01.
Article
in English
| MEDLINE | ID: mdl-35293006
16.
Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability.
J Biol Chem
; 295(52): 18474-18484, 2020 12 25.
Article
in English
| MEDLINE | ID: mdl-33093170
17.
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Br J Haematol
; 195(2): 230-243, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34341985
18.
Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series.
Blood
; 143(8): 734-737, 2024 Feb 22.
Article
in English
| MEDLINE | ID: mdl-38096365
19.
Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data.
Ann Hematol
; 100(8): 2087-2093, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-33270162
20.
Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement.
Eur J Haematol
; 107(4): 449-457, 2021 Oct.
Article
in English
| MEDLINE | ID: mdl-34185342